Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

INTRODUCTION: The impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) receiving [(177)Lu]Lu-PSMA-617 therapy has been the subject of controversy. Therefore, WARMTH decided to plan a multicenter retrospective analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmadzadehfar, Hojjat, Rahbar, Kambiz, Baum, Richard P., Seifert, Robert, Kessel, Katharina, Bögemann, Martin, Kulkarni, Harshad R, Zhang, Jingjing, Gerke, Carolin, Fimmers, Rolf, Kratochwil, Clemens, Rathke, Hendrik, Ilhan, Harun, Maffey-Steffan, Johanna, Sathekge, Mike, Kabasakal, Levent, Garcia-Perez, Francisco Osvaldo, Kairemo, Kalevi, Maharaj, Masha, Paez, Diana, Virgolini, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835179/
https://www.ncbi.nlm.nih.gov/pubmed/32383093
http://dx.doi.org/10.1007/s00259-020-04797-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835179/
https://www.ncbi.nlm.nih.gov/pubmed/32383093
http://dx.doi.org/10.1007/s00259-020-04797-9

Ejemplares similares